Charles Kennergren

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2606930/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm, 2017, 14, e503-e551.	0.7	792
2	The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) Registry of Transvenous Lead Extraction Outcomes. European Heart Journal, 2017, 38, 2995-3005.	2.2	339
3	Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. New England Journal of Medicine, 2019, 380, 1895-1905.	27.0	251
4	2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRS. Europace, 2018, 20, 1217-1217.	1.7	243
5	A single-centre experience of over one thousand lead extractions. Europace, 2009, 11, 612-617.	1.7	185
6	Automatic Adjustment of Pacemaker Stimulation Output Correlated with Continuously Monitored Capture Thresholds: A Multicenter Study. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1567-1575.	1.2	100
7	Worldwide Randomized Antibiotic EnveloPe Infection PrevenTion Trial (WRAP-IT). American Heart Journal, 2016, 180, 12-21.	2.7	53
8	Cardiac Implantable Electronic Device Infection in Patients at Risk. Arrhythmia and Electrophysiology Review, 2016, 5, 65.	2.4	51
9	Bridge to surgery: Best practice protocol derived from early clinical experience with the Bridge Occlusion Balloon. Federated Agreement from the Eleventh Annual Lead Management Symposium. Heart Rhythm, 2017, 14, 1574-1578.	0.7	41
10	Impact of Cardiac Implantable Electronic Device Infection. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008280.	4.8	41
11	Cost-Effectiveness of an Antibacterial Envelope for Cardiac Implantable Electronic Device Infection Prevention in the US Healthcare System From the WRAP-IT Trial. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008503.	4.8	39
12	Risk stratification of patients undergoing transvenous lead extraction with the ELECTRa Registry Outcome Score (EROS): an ESC EHRA EORP European lead extraction ConTRolled ELECTRa registry analysis. Europace, 2021, 23, 1462-1471.	1.7	38
13	First European Experience Using Excimer Laser for the Extraction of Permanent Pacemaker Leads. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 268-270.	1.2	29
14	Cardiac lead extraction with a novel locking stylet. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 591-593.	1.3	25
15	A European perspective on lead extraction: Part I. Heart Rhythm, 2008, 5, 160-162.	0.7	22
16	The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction ConTRolled ELECTRa registry subanalysis. Europace, 2020, 22, 1718-1728.	1.7	22
17	Risk Factors for CIED Infection After Secondary Procedures. JACC: Clinical Electrophysiology, 2022, 8, 101-111.	3.2	20
18	Infectious consequences of hematoma from cardiac implantable electronic device procedures and the role of the antibiotic envelope: A WRAP-IT trial analysis. Heart Rhythm, 2021, 18, 2080-2086.	0.7	19

#	Article	IF	CITATIONS
19	Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England. Value in Health, 2021, 24, 930-938.	0.3	19
20	European perspective on lead extraction: Part II. Heart Rhythm, 2008, 5, 320-323.	0.7	18
21	Percutaneous occlusion balloon as a bridge to surgery in a swine model of superior vena cava perforation. Heart Rhythm, 2016, 13, 2215-2220.	0.7	16
22	Clinical Presentation, Timing, and Microbiology of CIED Infections. JACC: Clinical Electrophysiology, 2021, 7, 50-61.	3.2	11
23	Comparison of outcomes in infected cardiovascular implantable electronic devices between complete, partial, and failed lead removal: an ESC-EHRA-EORP ELECTRa (European Lead Extraction ConTrolled) registry. Europace, 2019, 21, 1876-1889.	1.7	10
24	Clinical Experience with an Automatic Threshold Tracking Algorithm Study. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 2219-2224.	1.2	9
25	Lead fixation mechanism impacts outcome of transvenous lead extraction: data from the European Lead Extraction ConTRolled Registry. Europace, 2022, 24, 817-827.	1.7	9
26	Clinical impact of antithrombotic therapy in transvenous lead extraction complications: a sub-analysis from the ESC-EORP EHRA ELECTRa (European Lead Extraction ConTRolled) Registry. Europace, 2019, 21, 1096-1105.	1.7	8
27	Management of Cardiovascular Implantable Electronic Devices Infections in High-Risk Patients. Arrhythmia and Electrophysiology Review, 2015, 4, 53.	2.4	8
28	Low-temperature electrocautery reduces adverse effects from secondary cardiac implantable electronic device procedures: Insights from the WRAP-IT trial. Heart Rhythm, 2021, 18, 1142-1150.	0.7	7
29	Coronary Sinus Lead Removal: A Comparison between Active and Passive Fixation Leads. PLoS ONE, 2016, 11, e0153651.	2.5	5
30	Clinical performance of implantable cardioverter-defibrillator lead monitoring diagnostics. Heart Rhythm, 2022, 19, 363-371.	0.7	5
31	Machine learning–derived major adverse event prediction of patients undergoing transvenous lead extraction: Using the ESC EHRA EORP European lead extraction ConTRolled ELECTRa registry. Heart Rhythm, 2022, 19, 885-893.	0.7	5
32	Transvenous lead extraction procedures in women based on ESC-EHRA EORP European Lead Extraction ConTRolled ELECTRa registry: is female sex a predictor of complications?. Europace, 2019, 21, 1890-1899.	1.7	4
33	Bidirectional Defibrillation Using Implantable Defibrillators: A Prospective Randomized Comparison Between Pectoral and Abdominal Active Generators. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 1343-1353.	1.2	3
34	Risk factors for hematoma in patients undergoing cardiac device procedures: A WRAP-IT trial analysis. Heart Rhythm O2, 2022, 3, 466-473.	1.7	3
35	A Case of Pacemaker Endocarditis Caused by Aerococcus urinae. Case Reports in Infectious Diseases, 2018, 2018, 1-3.	0.5	2
36	Short-and Long-Term Performance of a Tripolar Down-Sized Single Lead for Implantable Cardioverter Defibrillator Treatment: A Randomized Prospective European Multicenter Study. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 2087-2094.	1.2	1

#	Article	IF	CITATIONS
37	Impact of anticoagulationÂtherapy on outcomes in patients with cardiac implantable resynchronization devices undergoing transvenous lead extraction: A substudy of the ESCâ€EHRA EORP ELECTRa (European Lead Extraction ConTRolled) Registry. Journal of Cardiovascular Electrophysiology, 2019, 30, 1086-1095.	1.7	1
38	The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction ConTRolled ELECTRa Registry subanalysis—Author's reply. Europace, 2021, 23, 1149-1150.	1.7	1